Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Event, Webcast

Guardant Health to Participate in Upcoming March Investor Conferences


Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the following investor conferences.

Interested parties may access a live and archived webcast of the presentation on the "Investors" section of the company website at: www.guardanthealth.com.

About Guardant Health

Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health has commercially launched Guardant360®, Guardant360 CDx, Guardant360 TissueNexttm, Guardant360 Responsetm, and GuardantINFINITYtm tests for advanced-stage cancer, and Guardant Revealtm for early-stage cancer. The Guardant Health screening portfolio, including the commercially launched Shieldtm test, aims to address the needs of individuals eligible for cancer screening. For more information, visit guardanthealth.com and follow the company on LinkedIn and Twitter.


These press releases may also interest you

at 12:20
The "Regenerative Medicine Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering. Regenerative Medicine Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented...

at 12:10
The "Diagnostic Imaging Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering. Diagnostic Imaging Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to...

at 12:05
King Faisal Specialist Hospital & Research Centre (KFSH&RC) has achieved a significant milestone in its Robotic Cardiac Surgery Program, which was initiated in February 2019. Within its first year, the program performed 105 cardiac procedures. As of...

at 11:55
The "Infectious Vaccine Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering. Infectious Vaccine Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to...

at 11:40
The "Musculoskeletal Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering. Musculoskeletal Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the...

at 11:30
The "Option and Evaluation Deals in Pharmaceuticals and Biotechnology 2016-2024" report has been added to ResearchAndMarkets.com's offering. Fully revised and updated, the report provides details of option and evaluation deals from 2016 to 2024....



News published on and distributed by: